Exacerbation ob underlying IPF, was deemed unrelated to the drug in the paper by Ikeda et al., because rechallenge with the drug did not lead to relapse of the exacerbation in the patient

Generally-speaking, evidence for nintedanib-induced ILD is low-to-very low